CureVac
Dr. Eva Bok possesses extensive experience in quality control and analytical methods within the biopharmaceutical industry. Currently serving as QC Manager for ASAT Strategy at CureVac since October 2021, Dr. Bok leads a team focused on reference materials management, analytical transfer, and continuous improvement projects. Prior to this role, Dr. Bok was QC Manager at Rentschler Biopharma SE, where expertise in capillary electrophoresis methods was demonstrated. Education includes a Ph.D. in Biology from the University of Tübingen, alongside a Master of Science and Bachelor of Science in Biology from the University of Hohenheim.
This person is not in any teams
CureVac
8 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.